Amygdala Neurosciences is focused on developing innovative treatments for substance use disorders (SUD) through the discovery of first-in-class medicines. Their primary compound, ANS-858, is a selective, reversible inhibitor of the enzyme ALDH2, which plays a crucial role in the metabolism of various addictive substances. This compound has been identified from a rigorous drug discovery program that screened over 1,000 synthesized compounds. ANS-858 is currently in preclinical development and is designed to reduce the self-administration of addictive chemicals such as alcohol, nicotine, cocaine, and opiates, with a particular emphasis on addressing alcohol use disorder.

In addition to its potential in treating addiction, research indicates that ANS-858 may also alleviate anxiety-like behaviors, suggesting a dual therapeutic effect. The inhibition of ALDH2 not only targets the compulsive behaviors associated with substance use but may also provide benefits for individuals suffering from co-occurring mental health disorders. This positions ANS-858 as a promising candidate for a more comprehensive approach to addiction treatment, potentially enhancing the existing therapeutic options available for individuals struggling with substance misuse.

United States

Amygdala Neurosciences is a biopharmaceutical company whose mission is to invent and develop first-in-class medicines to treat substance use disorders (SUD). Amygdala Neurosciences, headquartered in San Francisco, CA, is an independent small biopharmaceutical company founded in 2015.

Amygdala Neurosciences

Company Details